Alzheon, Inc. announced that it has strengthened its commercial organization with the promotion of Glenn E. Pauly to Chief Commercial Officer. These appointments will support preparations for the commercial launch of investigational agent ALZ-801, which is currently being evaluated in the APOLLOE4 Phase 3 trial in Early Alzheimer?s disease patients with two copies of the APOE4 gene. Mr. Pauly joined Alzheon in July of 2022 as the Head of Commercial, where he began the process of internal planning and building of organizational infrastructure to support preparations for a commercial launch of ALZ-801.

He has more than 20 years of commercial launch, sales, market access, and leadership experience in the biopharmaceutical industry. Prior to joining Alzheon, Mr. Pauly was the West Division General Manager and Vice President at Biogen with responsibility for the launch of the anti-amyloid antibody Aduhelm®. Previously, he held roles at Johnson & Johnson, Genentech, and AstraZeneca, where he supported launches and commercialization for multiple products including Remicade®, Actemra®, Xolair®, and Fasenra®.